Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Anders Rosengren

Postdoctoral research fellow

Default user image.

Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

Author

  • Annika S. Axelsson
  • Emily Tubbs
  • Brig Mecham
  • Shaji Chacko
  • Hannah A. Nenonen
  • Yunzhao Tang
  • Jed W. Fahey
  • Jonathan M.J. Derry
  • Claes B. Wollheim
  • Nils Wierup
  • Morey W Haymond
  • Stephen H. Friend
  • Hindrik Mulder
  • Anders H. Rosengren

Summary, in English

A potentially useful approach for drug discovery is to connect gene expression profiles of disease-affected tissues ("disease signatures") to drug signatures, but it remains to be shown whether it can be used to identify clinically relevant treatment options. We analyzed coexpression networks and genetic data to identify a disease signature for type 2 diabetes in liver tissue. By interrogating a library of 3800 drug signatures, we identified sulforaphane as a compound that may reverse the disease signature. Sulforaphane suppressed glucose production from hepatic cells by nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and decreased expression of key enzymes in gluconeogenesis. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of metformin. Finally, sulforaphane, provided as concentrated broccoli sprout extract, reduced fasting blood glucose and glycated hemoglobin (HbA1c) in obese patients with dysregulated type 2 diabetes.

Department/s

  • Diabetes - Islet Patophysiology
  • Diabetic Complications
  • Neuroendocrine Cell Biology
  • Diabetes - Molecular Metabolism
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2017-06-14

Language

English

Publication/Series

Science Translational Medicine

Volume

9

Issue

394

Document type

Journal article

Publisher

American Association for the Advancement of Science (AAAS)

Topic

  • Endocrinology and Diabetes

Status

Published

Research group

  • Diabetes - Islet Patophysiology
  • Diabetic Complications
  • Neuroendocrine Cell Biology
  • Diabetes - Molecular Metabolism

ISBN/ISSN/Other

  • ISSN: 1946-6234